VENTURE LIFE GROUP PLC

Report Publication Announcement • Sep 29, 2025

National Storage Mechanism | Additional information

RNS Number : 2381B

Venture Life Group PLC

29 September 2025

29 September 2025

VENTURE LIFE GROUP PLC

("Venture Life", "VLG" or the "Group")

Investor Presentation via Investor Meet Company

Venture Life (AIM: VLG) is pleased to announce that Jerry Randall (CEO) and Daniel Wells (CFO) will provide a live presentation relating to the Interim Results for the period ended 30 June 2025 via Investor Meet Company on 01 October 2025, 14:30 BST.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 30 September 2025, 09:00 BST, or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet Venture Life Group plc via:

https://www.investormeetcompany.com/venture-life-group-plc/register-investor

Investors who already follow Venture Life Group plc on the Investor Meet Company platform will automatically be invited.

For further information, please contact:

Venture Life Group PLC                                                                                                     +44 (0) 1344 578004

Jerry Randall, Chief Executive Officer

Daniel Wells, Chief Financial Officer

Cavendish Capital Markets Limited (Nomad and Broker)                                              +44 (0) 20 7720 0500 

Stephen Keys/George Lawson (Corporate Finance)

Michael Johnson (Sales) 

About Venture Life ( www.venture-life.com )

Venture Life is an international consumer self-care company focused on commercialising products for the global self-care market. Headquartered in the UK, the Group's product portfolio includes Balance Activ in the area of women's intimate healthcare, Earol® supporting ENT care, Lift and Glucogel product ranges for energy and glucose management and hypoglycaemia, plus the Health & Her product range supporting the hormonal lifecycle.

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through health & beauty stores, pharmacies, grocery multiples and e-commerce channels and are sold globally. In the UK,  Ireland and the USA these are supplied direct by the company to retailers, elsewhere they are supplied by the Group's international distribution partners. 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCFKLFLEKLFBBV